Clinical Trial Update: Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer [Phase 1]

View source ↗

Summary

Phase 1 study evaluating AUY922 (luminespib) with cetuximab in KRAS wild-type metastatic colorectal cancer has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colon Cancer
• Colorectal Cancer
• Rectal Cancer

Drugs mentioned

• AUY922 (luminespib)
• Cetuximab (cetuximab)

Snippet

Sponsor: Swedish Medical Center | Conditions: Recurrent Colon Cancer, Recurrent Rectal Cancer | Phase 1 | Status: COMPLETED